Zenith Drugs Limited (NSE: ZENITHDRUG) is an Indore, Madhya Pradesh-based company in the Pharmaceuticals industry. With a market capitalisation of ₹68 Cr, it ranks #3,567 by market cap among the 6,197 Indian listed companies on FinBizNet, and #49 of 63 in Pharmaceuticals. At ₹42.85 (as of 16 Nov 2026), the share price is 28.2% below its 52-week high of ₹59.65 and 28.7% above its 52-week low of ₹33.30. The share price is down 32.1% over one year and down 3.0% over three months.
| Current Price | ₹42.85 |
|---|---|
| Market Cap | ₹68 Cr |
| NSE Symbol | ZENITHDRUG |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 18.6 |
| Return on Equity | 5.52% |
| Return on Assets | 3.47% |
| 52-Week Range | ₹33.30 – ₹59.65 |
| 1-Year Price Change | -32.1% |
| 3-Month Price Change | -3.0% |
| Beta (1Y) | 0.71 |
| Dividend Yield | 0.00% |
| Headquarters | Indore, Madhya Pradesh |
| Website | zenithdrugs.com |
Promoters held 69.98% of Zenith Drugs Limited's shares as of Mar 2026, unchanged from Mar 2025.
Zenith Drugs Limited, together with its subsidiaries, manufactures and trades in branded, generic, and OTC medicines. The company offers a range of pharmaceutical formulations, such as ORS powder, liquid orals, ointments, creams, gels, liquid externals, capsules, and tablets. Its products are indicated for allergology, general analytics, infections, genetics, endocrinology, and microbiology. The company operates in India, Costa Rica, Mauritius, Cambodia, Myanmar, Yemen, Sierra, Leone, Liberia, and Bhutan. Zenith Drugs Limited was incorporated in 1956 and is based in Indore, India.
1. Manufacturing and Trading of Medicines-This segment engages in manufacturing and trading medicines. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing and Trading of Medicines-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Zenith Drugs Limited | ₹68 Cr | 18.6 | 5.52% | — | -32.1% |
Listed by market capitalisation. Ratios are shown for context only.
Zenith Drugs Limited is trading at ₹42.85, with a market capitalisation of ₹68 Cr.
Zenith Drugs Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Zenith Drugs Limited has a P/E of 18.6 and a return on equity of 5.52%.
Zenith Drugs Limited is listed on the NSE under the symbol ZENITHDRUG.
Zenith Drugs Limited's share price is down 32.1% over one year and down 3.0% over three months. Its 52-week range is ₹33.30 to ₹59.65.
Promoters held 69.98% of Zenith Drugs Limited's shares as of Mar 2026, unchanged from Mar 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.